tiprankstipranks
Advertisement
Advertisement

NURPF Stock Latest News

Neuren deepens rare disease push as Phase 3 PMS trial gains momentum
Company AnnouncementsNeuren deepens rare disease push as Phase 3 PMS trial gains momentum
11d ago
Neuren Set for Major EU Milestone as EMA Backs DAYBU for Rett Syndrome
PremiumCompany Announcements
Neuren Set for Major EU Milestone as EMA Backs DAYBU for Rett Syndrome
1M ago
Neuren Pharmaceuticals Seeks ASX Quotation for 450,000 New Shares
PremiumCompany Announcements
Neuren Pharmaceuticals Seeks ASX Quotation for 450,000 New Shares
2M ago
Neuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme
PremiumCompany Announcements
Neuren Issues 360,000 Unquoted Shares Under Employee Incentive Scheme
2M ago
Neuren Investors Back Board and CEO Options but Reject Constitution Changes
PremiumCompany Announcements
Neuren Investors Back Board and CEO Options but Reject Constitution Changes
2M ago
Neuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological Disorders
PremiumCompany AnnouncementsNeuren Leverages DAYBUE Windfall to Drive NNZ-2591 Phase 3 Push in Rare Neurological Disorders
2M ago
Neuren Advances NNZ-2591 Into Phase 3 Extension, Deepening Its Rare-Disease Pipeline
Premium
Company Announcements
Neuren Advances NNZ-2591 Into Phase 3 Extension, Deepening Its Rare-Disease Pipeline
2M ago
NURPF
Neuren launches Investor Hub to bolster engagement as neurological pipeline advances
Premium
Company Announcements
Neuren launches Investor Hub to bolster engagement as neurological pipeline advances
3M ago
Neuren Pharmaceuticals Updates Daily On‑Market Share Buy‑Back Activity
PremiumCompany Announcements
Neuren Pharmaceuticals Updates Daily On‑Market Share Buy‑Back Activity
3M ago
Neuren Rides 20% DAYBUE Sales Growth and Strong STIX Launch in Q1 2026
PremiumCompany Announcements
Neuren Rides 20% DAYBUE Sales Growth and Strong STIX Launch in Q1 2026
3M ago
Neuren Updates Market on Ongoing On-Market Share Buy-Back
PremiumCompany Announcements
Neuren Updates Market on Ongoing On-Market Share Buy-Back
3M ago
Neuren Pharmaceuticals Outlines Procedures for Virtual Shareholder Meeting
PremiumCompany Announcements
Neuren Pharmaceuticals Outlines Procedures for Virtual Shareholder Meeting
3M ago
Neuren Sets Hybrid 2026 AGM, Puts Director Re-election to Shareholder Vote
PremiumCompany AnnouncementsNeuren Sets Hybrid 2026 AGM, Puts Director Re-election to Shareholder Vote
3M ago
Neuren Files Updated ASX Governance Appendix, Confirms Compliance With Key Standards
Premium
Company Announcements
Neuren Files Updated ASX Governance Appendix, Confirms Compliance With Key Standards
3M ago
Neuren details 2025 progress and governance in latest annual report
Premium
Company Announcements
Neuren details 2025 progress and governance in latest annual report
3M ago
Neuren Updates Market on Ongoing On‑Market Share Buy‑Back
PremiumCompany Announcements
Neuren Updates Market on Ongoing On‑Market Share Buy‑Back
4M ago
Neuren Pharmaceuticals Updates Market on Ongoing Share Buy-Back
PremiumCompany Announcements
Neuren Pharmaceuticals Updates Market on Ongoing Share Buy-Back
4M ago
Neuren Updates Market on Progress of On-Market Share Buy-Back
PremiumCompany Announcements
Neuren Updates Market on Progress of On-Market Share Buy-Back
4M ago
Neuren Cancels Shares Following On-Market Buy-Back
PremiumCompany Announcements
Neuren Cancels Shares Following On-Market Buy-Back
4M ago
Neuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-Available
PremiumCompany AnnouncementsNeuren Expands Rett Syndrome Reach as DAYBUE STIX Goes Broadly U.S.-Available
4M ago
Neuren Pharmaceuticals Reports Lapse of 50,000 Conditional Options
Premium
Company Announcements
Neuren Pharmaceuticals Reports Lapse of 50,000 Conditional Options
4M ago
Neuren updates market on ongoing on‑market share buy‑back
Premium
Company Announcements
Neuren updates market on ongoing on‑market share buy‑back
4M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >